Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | GAA | P10253 | 7/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | GLA | P06280 | 6/20 | 0.34 |
| ▸ | HPGD | P15428 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597235 | 0.88 | CCNK (0.35) | CA12CA9DDR1 | |
| SCHEMBL1661441 | 0.86 | ALDH1A1 (0.36) | SCN9AALDH1A1GAAKDM4EGLA | |
| SCHEMBL14773413 | 0.85 | ALDH1A1 (0.33) | SCN9AALDH1A1GAAKDM4EGLA | |
| SCHEMBL1661230 | 0.85 | CYP1A2 (0.39) | SCN9ALIPGCA12CA9DDR1 | |
| SCHEMBL1661031 | 0.83 | CA12 (0.39) | CA12CA9MPOXDHDDR1 | |
| SCHEMBL1660573 | 0.81 | CA12 (0.35) | CA12CA9DDR1 | |
| SCHEMBL1001057 | 0.81 | CYP1A2 (0.36) | SCN9ACA12CA9DDR1 | |
| SCHEMBL2390655 | 0.79 | DDR1 (0.33) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL2389551 | 0.78 | — | — | |
| SCHEMBL12180687 | 0.78 | PIK3CD (0.36) | SCN9AALDH1A1KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | claimed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | claimed |
| EP-2585070-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | claimed |
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | claimed |
| WO-2013036224-A1 | USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | claimed |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2011161249-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | claimed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | SCN9A 268/4885ALDH1A1 529/4885GAA 1392/4885 |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | GRM1, GRIK2, GRIK1 | SCN9A 815/4885ALDH1A1 1492/4885GAA 2422/4885 |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | GRIK1, GRIK2, GRIK4 | SCN9A 598/4885ALDH1A1 777/4885GAA 2085/4885 |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | SCN9A 268/4885ALDH1A1 529/4885GAA 1392/4885 |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA1, GBA2 | SCN9A 1892/4885ALDH1A1 1050/4885GAA 25/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | SCN9A 276/4885ALDH1A1 804/4885GAA 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.